Literature DB >> 6155348

Cytomegalovirus-specific lymphocyte transformations in subjects of different ages with primary immunodeficiency.

T Tamura, S Chiba, W Abo, Y Chiba, T Nakao.   

Abstract

The role of specific cell-mediated immune responses in human cytomegalovirus (CMV) infections was studied by an in vitro lymphocyte transformation test, using a whole blood culture. CMV-induced in vitro lymphocyte proliferation was mainly dependent on the presence of sensitized T-cells. Three of five seronegative patients with B-cell deficiency showed positive lymphocyte responses to CMV antigen. In contrast, a patient with ataxia-telangiectasia who was shedding the virus in urine did not show a cellular response to either CMV or phytohemagglutinin. Age-related differences were found in the CMV lymphocyte transformation test. The responses were generally low (P less than 0.025) in infants and higher in older children and adults. CMV lymphocyte transformation responses were lower in 15 children who were excreting CMV in urine when tested than in 17 seropositive children who were not excreting the virus.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6155348      PMCID: PMC550892          DOI: 10.1128/iai.28.1.49-53.1980

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  EXTRACTION OF CELL-ASSOCIATED VIRUS WITHOUT DAMAGE OF THE CULTURE. (BRIEF REPORT).

Authors:  C HALLAUER; G KRONAUER
Journal:  Arch Gesamte Virusforsch       Date:  1965

2.  Application of a microtechnique to viral serological investigations.

Authors:  J L SEVER
Journal:  J Immunol       Date:  1962-03       Impact factor: 5.422

3.  Therapy of cytomegalovirus retinitis with transfer factor.

Authors:  M W Rytel; T M Aaberg; T H Dee; L H Heim
Journal:  Cell Immunol       Date:  1975-09       Impact factor: 4.868

4.  Induction of immune interferon by murine cytomegalovirus.

Authors:  E E Selkurt
Journal:  Proc Soc Exp Biol Med       Date:  1977-09

5.  Whole-blood culture technique for functional studies of lymphocyte reactivity to mitogens, antigens, and homologous lymphocytes.

Authors:  J L Pauly; J E Sokal; T Han
Journal:  J Lab Clin Med       Date:  1973-09

6.  Heterogeneity of human T lymphocytes to bind sheep erythrocytes and mitogenic responses of their subpopulations.

Authors:  M Sasaki; T Sekizawa; H Takahashi; T Abo; K Kumagai
Journal:  J Immunol       Date:  1975-12       Impact factor: 5.422

7.  Enhancement of murine cytomegalovirus infection during graft-vs.-host reaction.

Authors:  J N Dowling; B C Wu; J A Armstrong; M Ho
Journal:  J Infect Dis       Date:  1977-06       Impact factor: 5.226

8.  Progressive inhibition of T-cell function preceding clinical signs of cytomegalovirus infection in mice.

Authors:  J Booss; E F Wheelock
Journal:  J Infect Dis       Date:  1977-03       Impact factor: 5.226

9.  Incidence of cytomegaloviremia in blood-bank donors and in infants with congenital cytomegalic inclusion disease.

Authors:  R Mirkovic; J Werch; M A South; M Benyesh-Melnick
Journal:  Infect Immun       Date:  1971-01       Impact factor: 3.441

View more
  4 in total

1.  Studies on lymphocyte cell surface in ataxia-telangiectasia.

Authors:  N K Ozer; G Ciliv; A I Berkel; O Sanal; O Yeğin; F Ersoy
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

2.  Longitudinal studies of cytomegalovirus-specific cell-mediated immunity in congenitally infected infants.

Authors:  M Okabe; S Chiba; T Tamura; Y Chiba; T Nakao
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

3.  Peripheral blood mononuclear phagocytes mediate dissemination of murine cytomegalovirus.

Authors:  C A Stoddart; R D Cardin; J M Boname; W C Manning; G B Abenes; E S Mocarski
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

4.  Cytomegalovirus infection in infancy: virological and immunological studies.

Authors:  R C Gehrz; K M Linner; W R Christianson; A E Ohm; H H Balfour
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.